We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 1,971

Registering specific therapeutic indications: when the balance of convenience favours potential patent infringement

  • Houlihan2
  • -
  • Australia
  • -
  • April 23 2014

In a recent Decision, Warner-Lambert Company LLC v Apotex Pty Ltd 2014, the Federal Court of Australia granted a Patentee of an ARTG-registered

The COPAXONE story in the U.S. and India: to stay or not to stay is the question

  • Michael Best & Friedrich LLP
  • -
  • India, USA
  • -
  • April 23 2014

As an update to our March 5th, April 4th and April 9th postings, The Copaxone Story in the U.S. and India, The Copaxone Story in the U.S. and India:

Patent invalidations pave the way for cheaper breast cancer drugs this year: Hospira UK Ltd v Genentech Inc

  • Edwards Wildman Palmer LLP
  • -
  • United Kingdom
  • -
  • April 17 2014

The Intellectual Property Enterprise Court in London has found two patents related to the breast-cancer treatment drug Herceptin invalid, paving the

Notice of proposed amendment of the Pharmaceutical Affairs Act

  • Yoon & Yang LLC
  • -
  • South Korea
  • -
  • April 16 2014

On March 21, 2014, the Ministry of Food and Drug Safety ("MFDS") released for public consultation the proposed amendment (the "Proposed Amendment"

U.S. Supreme Court agrees to hear patent case that could impact timing of availability of more affordable multiple sclerosis treatment

  • Heslin Rothenberg Farley & Mesiti PC
  • -
  • USA
  • -
  • April 16 2014

The United States Supreme Court has granted certiorari in a patent case that could extend the market exclusivity of a top-selling multiple sclerosis

Edwards secures preliminary injunction against Medtronic

  • Knobbe Martens Olson & Bear LLP
  • -
  • USA
  • -
  • April 15 2014

On April 11, 2014, according to a press release, the U.S. District Court for the District of Delaware issued a preliminary injunction barring

High Court grants special leave to appeal extension of time in pharmaceutical patent case

  • King & Wood Mallesons
  • -
  • Australia
  • -
  • April 15 2014

Last Friday the High Court of Australia granted Alphapharm special leave to appeal from a decision of the Full Federal Court in Aspen Pharma Pty Ltd

Venlafaxine section 8 decision follows “roadmap” set out in previous decisions

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • April 14 2014

In this decision under section 8 of the Patented Medicines (Notice of Compliance) Regulations ("Regulations"), Justice Zinn of the Federal Court

Is there a way to patent stem cells in Europe?

  • FRKelly
  • -
  • European Union
  • -
  • April 14 2014

It's no news that the European Patent Convention (EPC) does not allow European Patents to be granted in respect of biotechnological inventions

“Perfect match” of claims and the authorized product required for patent listing under the NOC regulations

  • Norton Rose Fulbright LLP
  • -
  • Canada
  • -
  • April 11 2014

This was an application for judicial review of a decision of the Minister of Health (“Minister”) which denied the listing of Eli Lilly Canada Inc.’s